Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Nabil Al-Zaqri, T. Pooventhiran, Ali Alsalme, D. Jagadeeswara Rao, Siriki Srinivasa Rao, A. Sankar & Renjith Thomas. (2022) First-Principle Studies of Istradefylline with Emphasis on the Stability, Reactivity, Interactions and Wavefunction-Dependent Properties. Polycyclic Aromatic Compounds 42:6, pages 3238-3252.
Read now
Read now
Zhi-jun Li, Qian Wu & Chen-ju Yi. (2015) Clinical efficacy of istradefylline versus rTMS on Parkinson’s disease in a randomized clinical trial. Current Medical Research and Opinion 31:11, pages 2055-2058.
Read now
Read now
Thomas Müller. (2015) The safety of istradefylline for the treatment of Parkinson’s disease. Expert Opinion on Drug Safety 14:5, pages 769-775.
Read now
Read now
Santiago Perez-Lloret & Marcelo Merello. (2014) Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant. Expert Opinion on Pharmacotherapy 15:8, pages 1097-1107.
Read now
Read now
Melanie Mediavilla-Varela, Kimberly Luddy, David Noyes, Farah K Khalil, Anthony M Neuger, Hatem Soliman & Scott J Antonia. (2013) Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biology & Therapy 14:9, pages 860-868.
Read now
Read now
Petra Dunkel, Christina LL Chai, Beáta Sperlágh, Paul B Huleatt & Péter Mátyus. (2012) Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. Expert Opinion on Investigational Drugs 21:9, pages 1267-1308.
Read now
Read now
Articles from other publishers (20)
Yiyun Wang, Hongyi Wang, Haojie Xu, Zhonghui Zheng, Zihui Meng, Zhibin Xu, Jiarong Li & Min Xue. (2022) Design and synthesis of five‐membered heterocyclic derivatives of istradefylline with comparable pharmacological activity. Chemical Biology & Drug Design 100:4, pages 534-552.
Crossref
Crossref
Xiaoqin Hu, Jinhuan Ni, Nanyong Gao, Zhize Ye, Guoxin Hu, Jianping Cai & Jianchang Qian. (2022) The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline. Chemico-Biological Interactions 366, pages 110123.
Crossref
Crossref
Timothy A. Yap, Eileen E. Parkes, Weiyi Peng, Justin T. Moyers, Michael A. Curran & Hussein A. Tawbi. (2021) Development of Immunotherapy Combination Strategies in Cancer. Cancer Discovery 11:6, pages 1368-1397.
Crossref
Crossref
Subashini Raman, Syed Mahmood, Ayah R. Hilles & Azizur Rahman. (2021) Parkinson’s Disease - A Review on Advances and Treatment Strategies. Materials Science Forum 1025, pages 230-235.
Crossref
Crossref
Yiyun Wang, Haojie Xu, Hongyi Wang, Zhonghui Zheng, Zihui Meng, Zhibin Xu, Jiarong Li & Min Xue. (2021)
Design, Synthesis, and Biological Activity Studies of Istradefylline Derivatives Based on Adenine as A
2A
Receptor Antagonists
. ACS Omega 6:6, pages 4386-4394.
Crossref
Crossref
Amnon A. Berger, Ariel Winnick, Alexandra Welschmeyer, Alicia Kaneb, Kevin Berardino, Elyse M. Cornett, Alan D. Kaye, Omar Viswanath & Ivan Urits. (2020) Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review. Neurology International 12:3, pages 109-129.
Crossref
Crossref
Daniel Marx, Lukas M. Wingen, Gregor Schnakenburg, Christa E. Müller & Matthias S. Scholz. (2019) Fast, Efficient, and Versatile Synthesis of 6-amino-5-carboxamidouracils as Precursors for 8-Substituted Xanthines. Frontiers in Chemistry 7.
Crossref
Crossref
Nobutaka Hattori, Masashi Kikuchi, Noriaki Adachi, David Hewitt, Susan Huyck & Tadayuki Saito. (2016) Adjunctive preladenant: A placebo-controlled, dose-finding study in Japanese patients with Parkinson's disease. Parkinsonism & Related Disorders 32, pages 73-79.
Crossref
Crossref
Paul A. Beavis, Nicole Milenkovski, Melissa A. Henderson, Liza B. John, Bertrand Allard, Sherene Loi, Michael H. Kershaw, John Stagg & Phillip K. Darcy. (2015) Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses. Cancer Immunology Research 3:5, pages 506-517.
Crossref
Crossref
Małgorzata Zygmunt, Krystyna Gołembiowska, Anna Drabczyńska, Katarzyna Kieć-Kononowicz & Jacek Sapa. (2015) Anti-inflammatory, antioxidant, and antiparkinsonian effects of adenosine A2A receptor antagonists. Pharmacology Biochemistry and Behavior 132, pages 71-78.
Crossref
Crossref
Hong X. Ding, Carolyn A. Leverett, Robert E. KyneJr.Jr., Kevin K.-C. Liu, Sarah J. Fink, Andrew C. Flick & Christopher J. O’Donnell. (2015) Synthetic approaches to the 2013 new drugs. Bioorganic & Medicinal Chemistry 23:9, pages 1895-1922.
Crossref
Crossref
Tomoyoshi Kondo & Yoshikuni Mizuno. (2015) A Long-Term Study of Istradefylline Safety and Efficacy in Patients With Parkinson Disease. Clinical Neuropharmacology 38:2, pages 41-46.
Crossref
Crossref
John R. Atack, Brian C. Shook, Stefanie Rassnick, Paul F. Jackson, Kenneth Rhodes, Wilhelmus H. Drinkenburg, Abdallah Ahnaou, Paula te Riele, Xavier Langlois, Brian Hrupka, Patrick De Haes, Herman Hendrickx, Nancy Aerts, Koen Hens, Annemie Wellens, Jef Vermeire & Anton A. H. P. Megens. (2014)
JNJ-40255293, a Novel Adenosine A
2A
/A
1
Antagonist with Efficacy in Preclinical Models of Parkinson’s Disease
. ACS Chemical Neuroscience 5:10, pages 1005-1019.
Crossref
Crossref
Marc Brugarolas, Gemma Navarro, Eva Martínez-Pinilla, Edgar Angelats, Vicent Casadó, José L. Lanciego & Rafael Franco. (2014) G-Protein-Coupled Receptor Heteromers as Key Players in the Molecular Architecture of the Central Nervous System. CNS Neuroscience & Therapeutics 20:8, pages 703-709.
Crossref
Crossref
Albert Y. Hung & Michael A. Schwarzschild. (2013) Treatment of Parkinson’s Disease: What’s in the Non-dopaminergic Pipeline?. Neurotherapeutics 11:1, pages 34-46.
Crossref
Crossref
Paul A. BeavisUpulie DivisekeraChristophe PagetMelvyn T. ChowLiza B. JohnChristel DevaudKaren DwyerJohn StaggMark J. Smyth & Phillip K. Darcy. (2013)
Blockade of A
2A
receptors potently suppresses the metastasis of CD73
+
tumors
. Proceedings of the National Academy of Sciences 110:36, pages 14711-14716.
Crossref
Crossref
Yoshikuni Mizuno & Tomoyoshi Kondo. (2013)
Adenosine A
2A
receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
. Movement Disorders 28:8, pages 1138-1141.
Crossref
Crossref
Tom Foltynie & Joshua Kahan. (2013) Parkinson’s disease: an update on pathogenesis and treatment. Journal of Neurology 260:5, pages 1433-1440.
Crossref
Crossref
Silvia Rivara, Giovanni Piersanti, Francesca Bartoccini, Giuseppe Diamantini, Daniele Pala, Teresa Riccioni, Maria Antonietta Stasi, Walter Cabri, Franco Borsini, Marco Mor, Giorgio Tarzia & Patrizia Minetti. (2013)
Synthesis of (
E
)-8-(3-Chlorostyryl)caffeine Analogues Leading to 9-Deazaxanthine Derivatives as Dual A
2A
Antagonists/MAO-B Inhibitors
. Journal of Medicinal Chemistry 56:3, pages 1247-1261.
Crossref
Crossref
Lorraine V. Kalia, Jonathan M. Brotchie & Susan H. Fox. (2012) Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials. Movement Disorders 28:2, pages 131-144.
Crossref
Crossref